Jazz Pharmaceuticals, Inc.

368 articles with Jazz Pharmaceuticals, Inc.

• Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc

  6/17/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business.

• Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community

  6/14/2021

  Nothing Small About It (www.nothingsmallaboutit.com) is a support and educational resource center that spotlights and honors the experiences of people living with small cell lung cancer.

• Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021

  5/26/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 1:00 p.m. ET / 6:00 p.m. IST.

• Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

  5/20/2021

  Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021 and five abstracts at the virtual 26th Annual Congress of the European Hematology Association (EHA2021) from June 9 –16, 2021.

• Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021

  5/4/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the following virtual investor conferences:

• Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results

  5/4/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.

• Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering

  4/29/2021

  Jazz Pharmaceuticals plc announced the closing of its previously announced offering of $1.5 billion in aggregate principal amount of 4.375% senior secured notes due 2029 by Jazz Securities Designated Activity Company, a direct wholly owned subsidiary of the Company.

• GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

  4/23/2021

  GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today.

• Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering

  4/22/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 billion in an aggregate principal amount of 4.375% senior secured notes due 2029 (the "Notes") by Jazz

• Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting

  4/20/2021

  Jazz will host an investor and analyst presentation via webcast today at 12:30 p.m. ET.

• Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes - Apr 20, 2021

  4/20/2021

  Jazz Pharmaceuticals plc announced that its wholly owned subsidiary, Jazz Securities Designated Activity Company, is commencing a private offering of senior secured notes in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, subject to market and other conditions.

• Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

  4/19/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss first quarter 2021 financial results

• Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia

  4/12/2021

  Final FDA decision anticipated by August 12 Phase 3 study results to be presented during AAN Annual Meeting Clinical Trials Plenary Session on April 20 Company to host investor webcast to review Phase 3 data on April 20 at 12:30 PM ET

• Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

  3/30/2021

   Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos ® (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML)

• Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum

  3/22/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa Valley Forum.

• Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia

  3/18/2021

  Initiative aims to generate awareness about idiopathic hypersomnia and encourage those who may be struggling with the sleep disorder to have effective discussions with their healthcare providers and supporters about their condition

• Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

  2/23/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.

• Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference

  2/17/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10 th Annual Global Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Wednesday, February 24, 2021

• Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

  2/16/2021

   Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav™

• Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021

  2/9/2021

  - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021 , after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT